<DOC>
	<DOCNO>NCT00921180</DOCNO>
	<brief_summary>Currently , peginterferon alfa-2a oral nucleos ( ) ides approved treatment HBeAg positive CHB , overall HBeAg seroconversion far satisfactory . Therefore , effort various combination currently available drug need improve overall response rate . The simultaneous combination therapy oral nucleoside peginterferon alfa-2a large-scaled randomize trial show superior response rate peginterferon alfa-2a monotherapy . Recently , sequential monotherapy lamivudine first 4 week , follow weekly peginterferon alfa-2a show favorable HBeAg seroconversion rate peginterferon alfa-2a monotherapy , base assumption early viral suppression lamivudine restore immune function facilitate later immunomodulatory response peginterferon alfa-2a . With recent introduction entecavir , potent oral nucleoside drug resistance , sequential monotherapy entecavir potently suppress HBV DNA 4 week treatment , may facilitate response peginterferon alfa-2a achieve HBeAg seroconversion . Therefore , aim conduct placebo control randomize control trial evaluate add entecavir early course therapy improve treatment response .</brief_summary>
	<brief_title>Entecavir Pegasys Sequential Therapy Versus Pegasys HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description>Chronic hepatitis B ( CHB ) prevalent world , estimate chronic carrier 350 million worldwide . Currently , peginterferon alfa-2a oral nucleos ( ) ides approved treatment HBeAg positive CHB , overall HBeAg seroconversion far satisfactory . Therefore , effort various combination currently available drug need improve overall response rate . The simultaneous combination therapy oral nucleoside peginterferon alfa-2a large-scaled randomize trial show superior response rate peginterferon alfa-2a monotherapy . Recently , sequential monotherapy lamivudine first 4 week , follow weekly peginterferon alfa-2a show favorable HBeAg seroconversion rate peginterferon alfa-2a monotherapy , base assumption early viral suppression lamivudine restore immune function facilitate later immunomodulatory response peginterferon alfa-2a . With recent introduction entecavir , potent oral nucleoside drug resistance , sequential monotherapy entecavir potently suppress HBV DNA 4 week treatment , may facilitate response peginterferon alfa-2a achieve HBeAg seroconversion . Therefore , aim conduct placebo control randomize control trial evaluate add entecavir early course therapy improve treatment response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Chronic hepatitis B ( presence HBsAg &gt; 6 month ) HBeAg persistence 3 month Age old 18 year HBV DNA &gt; 20,000 IU/mL 2 occasion Serum ALT level 2 10 fold upper limit normal ( ULN ) A liver biopsy compatible chronic hepatitis B Anemia ( hemoglobin &lt; 13 gram per deciliter men &lt; 12 gram per deciliter woman ) Neutropenia ( neutrophil count &lt; 1,500 per cubic milliliter ) Thrombocytopenia ( platelet &lt; 90,000 per cubic milliliter ) Coinfection hepatitis B virus ( HBV ) , hepatitis D virus ( HDV ) human immunodeficiency virus ( HIV ) Chronic alcohol abuse ( daily consumption &gt; 20 gram per day ) Decompensated liver disease ( ChildPugh class B C ) Serum creatinine level 1.5 time upper limit normal Autoimmune liver disease Neoplastic disease An organ transplant Immunosuppressive therapy Poorly control autoimmune disease , pulmonary disease , cardiac disease , psychiatric disease , neurological disease , diabetes mellitus Evidence drug abuse Unwilling contraception Known allergic reaction entecavir peginterferon alfa2a Unwilling sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Hepatitis B , chronic</keyword>
	<keyword>Peginterferon alfa-2a</keyword>
	<keyword>Entecavir</keyword>
</DOC>